Open | $9.460 |
Close | $9.440 |
Volume / Avg. | 1.760M / 2.122M |
Day Range | 8.960 - 9.630 |
52 Wk Range | 1.995 - 11.310 |
Market Cap | $1.403B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 59 |
Short Interest | 2.79% |
Days to Cover | 2.52 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Ocular Therapeutix (NASDAQ: OCUL) through any online brokerage.
Other companies in Ocular Therapeutix’s space includes: Supernus Pharmaceuticals (NASDAQ:SUPN), Verona Pharma (NASDAQ:VRNA), Tarsus Pharmaceuticals (NASDAQ:TARS), ANI Pharmaceuticals (NASDAQ:ANIP) and Neumora Therapeutics (NASDAQ:NMRA).
The latest price target for Ocular Therapeutix (NASDAQ: OCUL) was reported by JMP Securities on Wednesday, March 13, 2024. The analyst firm set a price target for 24.00 expecting OCUL to rise to within 12 months (a possible 154.24% upside). 16 analyst firms have reported ratings in the last year.
The stock price for Ocular Therapeutix (NASDAQ: OCUL) is $9.44 last updated March 18, 2024 at 4:00 PM EDT.
There are no upcoming dividends for Ocular Therapeutix.
Ocular Therapeutix’s Q1 earnings are confirmed for Monday, May 6, 2024.
There is no upcoming split for Ocular Therapeutix.
Ocular Therapeutix is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.